Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Total article views   HTML views PDF downloads Totals
10,879 Dovepress* 9,920+ 1,671 11,591
PubMed Central* 959 360 1,319
Totals 10,879 2,031 12,910
*Since 29 June 2017
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 0 4

View citations on PubMed Central and Google Scholar